CLINICAL TRIALS PROFILE FOR INCOBOTULINUMTOXINA
✉ Email this page to a colleague
All Clinical Trials for incobotulinumtoxina
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00406367 ↗ | IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm | Completed | Merz Pharmaceuticals GmbH | Phase 3 | 2006-10-01 | Patients received one injection with incobotulinumtoxinA (Xeomin) or placebo at baseline. Thereafter, all patients who entered the Open-Label Extension Period (OLEX) received up to five injection sessions of incobotulinumtoxinA (Xeomin) during the OLEX period. |
| NCT00407030 ↗ | IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia | Completed | Merz Pharmaceuticals GmbH | Phase 3 | 2006-07-01 | At baseline patients received incobotulinumtoxinA (Xeomin) or placebo. Thereafter, all patients who entered the extension period were treated with up to five injection sessions of incobotulinumtoxinA (Xeomin) during the extension period. |
| NCT00430963 ↗ | IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines | Completed | Merz Pharmaceuticals GmbH | Phase 3 | 2006-10-01 | IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free of complexing proteins, i.e. free of proteins other than the active toxin. Injected into the muscle, IncobotulinumtoxinA (Xeomin) causes local weakening. Botulinum toxin type A is widely used for aesthetic treatment of facial lines. This study investigated the efficacy and safety of IncobotulinumtoxinA (Xeomin) in the treatment of glabellar frown lines compared to placebo. The study consisted of a Main Period and an Open-Label Extension [OLEX] Period of 120 days each. |
| NCT00432666 ↗ | IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb | Completed | Merz Pharmaceuticals GmbH | Phase 3 | 2006-06-01 | IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free from complexing proteins, i.e. free from proteins other than the active toxin. Injected into the muscle, incobotulinumtoxinA (Xeomin) causes local weakening. Botulinum toxin type A is widely used for treatment of various neurological conditions. This study will investigate the efficacy and safety of incobotulinumtoxinA (Xeomin) in the treatment of post-stroke spasticity of the upper limb. |
| NCT00465738 ↗ | IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity | Completed | Merz Pharmaceuticals GmbH | Phase 3 | 2007-02-01 | This study will investigate the efficacy and safety of incobotulinumtoxinA (Xeomin) in the treatment of arm tightness (upper limb spasticity) using two different dilutions of incobotulinumtoxinA (Xeomin). |
| NCT00507637 ↗ | Blepharospasm Short Interval | Terminated | Merz Pharmaceuticals GmbH | Phase 2 | 2007-08-01 | The objective of this Phase II study is to show that pre-treated patients with BEB with the need of shortened injection intervals achieve an improved and stable quality of life level if they receive repeated NT 201 injections at short injection intervals. In addition, the tolerability of repeated shortened NT 201 administrations in patients with BEB including the development of neutralizing antibodies will be investigated. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for incobotulinumtoxina
Condition Name
Clinical Trial Locations for incobotulinumtoxina
Trials by Country
Clinical Trial Progress for incobotulinumtoxina
Clinical Trial Phase
Clinical Trial Sponsors for incobotulinumtoxina
Sponsor Name
